Medications not yet evaluated by P&T are considered NON-FORMULARY . . . . . Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step! . . . . . Please be sure to document all clinical activities daily.
Search results for:

triamcinolone

triamcinolone
Drug Name Form Strength Formulary Unrestricted Formulary Restricted Non-Formulary Interchange
Azmacort AEROSOL WITH ADAPTER, INHALATION 100 mcg/inh    
Zilretta SOLUTION, INTRA-ARTICULAR 32 mg      
Kenalog SUSPENSION, INJECTABLE 10 mg/mL, 40 mg/mL      
VIEW MORE Androgens
CLASS
680800
Comments:

ORDERED FORMULATION

FORMULARY INTERCHANGE

NOTES

triamcinolone (Azmacort)

  • 100 mcg/inh
    • 4-10 puffs per day
    • 10-20 puffs per day
    • >20 puffs per day

mometasone (Asmanex Twisthaler)

  • 220 mcg/inh
    • 1 puff q evening
    • 2 puffs q evening
    • 2 puffs BID

Interchange for adult patients.

triamcinolone (Azmacort)

  • 100 mcg/inh
    • 4-10 puffs per day
  • 100 mcg/inh
    • 10-20 puffs per day
    • >20 puffs per day

mometasone (Asmanex HFA)

  • 100 mcg/ACT
    • 1 puff BID
  • 200 mcg/ACT
    • 1 puff BID
    • 2 puffs BID

Interchange for pediatric patients.

 

Zilretta: Formulary, restricted to Pain Center physicians for the FDA-approved indications. Use is limited to one dose, per knee, per patient lifetime.

 

 

Reviewed: March 23, 2005 (AZMACORT) and November 13, 2012 (Inhaled Corticosteroid Formulary), September 2025 (Zilretta)        

Triamcinolone acetonide (ZILRETTA) Spotlight.pdf

Last updated: Oct. 14, 2025






This site is intended for the staff of Huntsville Hospital.
While others may view accessible pages, Huntsville Hospital makes no warranty, express or implied,
as to the use of this information outside of Huntsville Hospital.
Please note than many documents are accessible via the provided link
only when connected to the Huntsville Hospital intranet.

Copyright © 2025 Rpharmy, LLC ­ All Rights Reserved